Philogen Spa PHIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €17.85
- Day Range
- €17.85–18.05
- 52-Week Range
- €14.60–19.25
- Bid/Ask
- €17.90 / €18.30
- Market Cap
- €723.20 Mil
- Volume/Avg
- 5,445 / 12,091
Key Statistics
- Price/Earnings (Normalized)
- 321.49
- Price/Sales
- 31.23
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.33%
Company Profile
Philogen Spa is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 165
- Website
- https://www.philogen.com
Comparables
Valuation
|
Metric
|
PHIL
|
ITM
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | 321.49 | 36.50 | 11.36 |
Price/Book Value | 8.02 | 0.97 | 3.12 |
Price/Sales | 31.23 | 2.47 | 5.50 |
Price/Cash Flow | — | 18.40 | 13.90 |
Price/Earnings
PHIL
ITM
PNT
Financial Strength
|
Metric
|
PHIL
|
ITM
|
PNT
|
|---|---|---|---|
Quick Ratio | 6.82 | 1.93 | 9.01 |
Current Ratio | 7.02 | 2.34 | 9.14 |
Interest Coverage | −11.02 | 4.26 | — |
Quick Ratio
PHIL
ITM
PNT
Profitability
|
Metric
|
PHIL
|
ITM
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −0.47% | 2.43% | 20.67% |
Return on Equity (Normalized) | −0.91% | 3.59% | 23.56% |
Return on Invested Capital (Normalized) | −0.46% | 4.17% | 23.38% |
Return on Assets
PHIL
ITM
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wtmtfnqd | Vjqy | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tppbbpn | Smhbwn | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vxzddrjy | Vyvjkh | $103.7 Bil | |
MRNA
| Moderna Inc | Nldkplwq | Tzw | $47.9 Bil | |
ARGX
| argenx SE ADR | Crlyvqy | Mwtbj | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Mssmcljr | Bmp | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sdzxqbnz | Wmlmcwp | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qjzjmbcm | Wxcjhfd | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cspggzgdmg | Kfzpy | $12.8 Bil | |
INCY
| Incyte Corp | Mcrkqtwx | Zcpwnzt | $12.1 Bil |